Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.

Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE.

Clin Cancer Res. 2014 May 15;20(10):2578-86. doi: 10.1158/1078-0432.CCR-14-0476.

PMID:
24831280
[PubMed - in process]
2.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

PMID:
24799347
[PubMed - in process]
3.

Analyses of the combination of 6-MP and dasatinib in cell culture.

Kaur G, Behrsing H, Parchment RE, Millin MD, Teicher BA.

Int J Oncol. 2013 Jul;43(1):13-22. doi: 10.3892/ijo.2013.1930. Epub 2013 May 2.

PMID:
23652925
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2012;7(12):e50494. doi: 10.1371/journal.pone.0050494. Epub 2012 Dec 28.

PMID:
23284638
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

In vitro exposure of precision-cut lung slices to 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride (NSC 710305, Phortress) increases inflammatory cytokine content and tissue damage.

Behrsing HP, Furniss MJ, Davis M, Tomaszewski JE, Parchment RE.

Toxicol Sci. 2013 Feb;131(2):470-9. doi: 10.1093/toxsci/kfs319. Epub 2012 Nov 9.

PMID:
23143926
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Advances in using PARP inhibitors to treat cancer.

Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.

BMC Med. 2012 Mar 9;10:25. doi: 10.1186/1741-7015-10-25. Review.

PMID:
22401667
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.

Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.

PMID:
22307137
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.

Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2011;6(10):e26152. doi: 10.1371/journal.pone.0026152. Epub 2011 Oct 10.

PMID:
22028822
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.

PMID:
21795476
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.

PMID:
20924131
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.

Clin Cancer Res. 2010 Sep 15;16(18):4532-42. doi: 10.1158/1078-0432.CCR-10-0523. Epub 2010 Sep 7. Review.

PMID:
20823146
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The statistics of phase 0 trials.

Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH.

Stat Med. 2010 May 10;29(10):1072-6. doi: 10.1002/sim.3840.

PMID:
20419759
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.

Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ.

Clin Cancer Res. 2010 Feb 1;16(3):1073-84. doi: 10.1158/1078-0432.CCR-09-2799. Epub 2010 Jan 26.

PMID:
20103672
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines.

Behrsing HP, Furniss MJ, Robillard KA, Tomaszewski JE, Parchment RE.

Cancer Chemother Pharmacol. 2010 May;65(6):1083-91. doi: 10.1007/s00280-009-1113-7. Epub 2009 Aug 29.

PMID:
19727731
[PubMed - indexed for MEDLINE]
15.

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE.

Mol Cancer. 2009 Jul 14;8:47. doi: 10.1186/1476-4598-8-47.

PMID:
19594950
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2009 Jul;8(7):1878-84. doi: 10.1158/1535-7163.MCT-09-0016. Epub 2009 Jul 7.

PMID:
19584232
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13.

PMID:
19364967
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP.

Invest New Drugs. 2009 Dec;27(6):571-8. doi: 10.1007/s10637-009-9228-6. Epub 2009 Feb 19.

PMID:
19225720
[PubMed - indexed for MEDLINE]
19.

Topoisomerase I inhibitors and drug resistance.

Parchment RE, Pessina A.

Cytotechnology. 1998 Sep;27(1-3):149-64. doi: 10.1023/A:1008008719699.

PMID:
19002789
[PubMed]
Free PMC Article
20.

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.

Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.

PMID:
18980982
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk